Recursion Pharmaceuticals, Inc.

NasdaqGS RXRX

Recursion Pharmaceuticals, Inc. Price to Sales Ratio (P/S) on February 06, 2025: 43.40

Recursion Pharmaceuticals, Inc. Price to Sales Ratio (P/S) is 43.40 on February 06, 2025, a -37.79% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Recursion Pharmaceuticals, Inc. 52-week high Price to Sales Ratio (P/S) is 114.21 on February 27, 2024, which is 163.18% above the current Price to Sales Ratio (P/S).
Recursion Pharmaceuticals, Inc. 52-week low Price to Sales Ratio (P/S) is 34.01 on November 22, 2024, which is -21.63% below the current Price to Sales Ratio (P/S).
Recursion Pharmaceuticals, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 56.95.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: RXRX

Recursion Pharmaceuticals, Inc.

CEO	Dr. Christopher C. Gibson Ph.D.
IPO Date	April 16, 2021
Location	United States
Headquarters	41 South Rio Grande Street
Employees	500
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Key trends

Past 5 years